Results 11 to 20 of about 2,399 (178)

Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics & Systems Pharmacology
Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH).
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Yuhuan Wang, Poulabi Banerjee, Robert Pordy, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +8 more
doaj   +2 more sources

Beyond lipids: Systemic effects of lipoprotein apheresis. [PDF]

Transfusion
Transfusion, Volume 66, Issue 3, Page 590-598, March 2026.
Nadim M, Akgun Y.
europepmc   +2 more sources

The High Price of Interrupted Follow-Up: Catastrophic Progression of Homozygous Familial Hypercholesterolemia-A Case Report and Literature Review. [PDF]

Clin Case Rep
ABSTRACT Familial hypercholesterolemia (FH) is the most common monogenic lipid disorder, primarily resulting from mutations in LDLR, APOB, and PCSK9 genes. These mutations cause persistently high levels of low‐density lipoprotein cholesterol (LDL‐C), predisposing affected individuals to premature atherosclerotic cardiovascular disease (ASCVD ...
Dastjerdi P, Aghababaei M, Nikfar R, Aghakouchakzadeh M, Mohseni-Badalabadi R, Hosseini K.   +5 more
europepmc   +2 more sources

LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection

Journal of Lipid Research, 2011
Subnormal HDL-cholesterol (HDL-C) and apolipoprotein (apo)AI levels are characteristic of familial hypercholesterolemia (FH), reflecting perturbed intravascular metabolism with compositional anomalies in HDL particles, including apoE enrichment. Does LDL-
Alexina Orsoni, Samir Saheb, Johannes H.M. Levels, Geesje Dallinga-Thie, Marielle Atassi, Randa Bittar, Paul Robillard, Eric Bruckert, Anatol Kontush, Alain Carrié, M. John Chapman   +10 more
doaj   +1 more source

Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundApheresis is an important treatment for reducing low‐density lipoprotein cholesterol (LDL‐C) in patients with familial hypercholesterolemia (FH). We systematically reviewed the current literature surrounding LDL‐C apheresis for FH.
Anthony Wang, Akshara Richhariya, Shravanthi R. Gandra, Brian Calimlim, Lisa Kim, Ruben G. W. Quek, Robert J. Nordyke, Peter P. Toth   +7 more
doaj   +1 more source

Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B

Journal of Lipid Research, 2000
Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates ...
Klaus G. Parhofer, P. Hugh R. Barrett, Thomas Demant, Peter Schwandt   +3 more
doaj   +1 more source

Real-World Safety Data From the World Apheresis Association Registry for the Spectra Optia Apheresis System. [PDF]

J Clin Apher
ABSTRACT In this study we analyzed 12 years of adverse events, (AE) data from the World Apheresis Association, (WAA) Registry specific to the Spectra Optia Apheresis System. We queried WAA Registry data, (2012–2023) on apheresis procedures performed exclusively on the Spectra Optia Apheresis System.
Haubner A, Mendoza S, Vrielink H, Witt V, Deeren D, Bojanic I, Gasova Z, Aandahl A, Glatt TN, Vasilache AM, Newman E, Strineholm V, Skosana Y, Stegmayr B.   +13 more
europepmc   +2 more sources

Preoperative Low-Density Lipoprotein Apheresis for Preventing Recurrence of Focal Segmental Glomerulosclerosis after Kidney Transplantation

Journal of Transplantation, 2018
Background. Focal segmental glomerulosclerosis (FSGS) often develops rapidly and frequently progresses to renal failure, while the recurrence rate after kidney transplantation is 20–50%.
Akihito Sannomiya, Toru Murakami, Ichiro Koyama, Kosaku Nitta, Ichiro Nakajima, Shohei Fuchinoue   +5 more
doaj   +1 more source

Role of lipoprotein apheresis in the management of familial hypercholesterolemia

Global Journal of Transfusion Medicine, 2021
Familial Hypercholesterolemia (FH) is an autosomal dominant disorder due to a congenital absence of low-density lipoprotein receptor (LDL-R) that transports cholesterol-carrying lipoprotein particles into cells.
Shamanna Seshadri Iyengar, Ambuja Kantharaj, Chandrashekar Shivaram, D S Hemantha Kumara, Roopa Murgod, G Shreedhara   +5 more
doaj   +1 more source

Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy.

Journal of Lipid Research, 1994
To determine the acute and long-term effects of low density lipoprotein (LDL) reduction on cholesterol biosynthesis, we studied changes in the cholesterol precursors mevalonic acid (MVA) and lathosterol in patients with heterozygous familial ...
M Pfohl, R P Naoumova, C Klass, W Knisel, B Jakober, T Risler, G R Thompson   +6 more
doaj   +1 more source